Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Tyra Biosciences, Inc.
13G/A
Amendment 2
TYRA · 90240B106
|
0% |
8/14/2026
Event 6/30/2026
|
|||
| Farallon Capital Management, L.L.C. | 0% | ||||
| Farallon Capital Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0% | ||||
| Four Crossings Institutional Partners V, L.P. | 0% | ||||
| Farallon Capital Offshore Investors II, L.P. | 0% | ||||
| Farallon Capital (AM) Investors, L.P. | 0% | ||||
| Farallon Capital F5 Master I, L.P. | 0% | ||||
| Farallon Healthcare Partners Master, L.P. | 0% | ||||
| Farallon Partners, L.L.C. | 0% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0% | ||||
| Farallon F5 (GP), L.L.C. | 0% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 0% | ||||
| Dapice Joshua J. | 0% | ||||
| Dreyfuss, Philip D. | 0% | ||||
| Dunn Hannah E. | 0% | ||||
| Gehani, Varun N. | 0% | ||||
| Giauque, Nicolas | 0% | ||||
| Husen, Avner A. | 0% | ||||
| Kim, David T. | 0% | ||||
| Linn, Michael G. | 0% | ||||
| Luo Patrick (Cheng) | 0% | ||||
| Roberts, Jr., Thomas G. | 0% | ||||
| Saito Edric C. | 0% | ||||
| Short Daniel S. | 0% | ||||
| Spokes, Andrew J. M. | 0% | ||||
| Warren, John R. | 0% | ||||
| Wehrly, Mark C. | 0% | ||||
|
Tango Therapeutics, Inc.
13G/A
Amendment 5
TNGX · 87583X109
|
9.8% |
8/14/2026
Event 6/30/2026
|
|||
| Farallon Capital Management, L.L.C. | 9.8% | ||||
| Farallon Capital Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0% | ||||
| Four Crossings Institutional Partners V, L.P. | 0% | ||||
| Farallon Capital Offshore Investors II, L.P. | 0% | ||||
| Farallon Capital (AM) Investors, L.P. | 0% | ||||
| Farallon Capital F5 Master I, L.P. | 0% | ||||
| Farallon Healthcare Partners Master, L.P. | 0% | ||||
| Farallon Partners, L.L.C. | 0% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0% | ||||
| Farallon F5 (GP), L.L.C. | 0% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 0% | ||||
| Dapice Joshua J. | 9.8% | ||||
| Dreyfuss, Philip D. | 9.8% | ||||
| Dunn Hannah E. | 9.8% | ||||
| Gehani, Varun N. | 9.8% | ||||
| Giauque, Nicolas | 9.8% | ||||
| Husen, Avner A. | 9.8% | ||||
| Kim, David T. | 9.8% | ||||
| Linn, Michael G. | 9.8% | ||||
| Luo Patrick (Cheng) | 9.8% | ||||
| Roberts, Jr., Thomas G. | 9.8% | ||||
| Saito Edric C. | 9.8% | ||||
| Short Daniel S. | 9.8% | ||||
| Spokes, Andrew J. M. | 9.8% | ||||
| Warren, John R. | 9.8% | ||||
| Wehrly, Mark C. | 9.8% | ||||
|
Savara Inc.
13G/A
Amendment 11
SVRA · 805111101
|
6.8% |
8/14/2026
Event 6/30/2026
|
|||
| Farallon Capital Management, L.L.C. | 6.8% | ||||
| Farallon Capital Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0% | ||||
| Four Crossings Institutional Partners V, L.P. | 0% | ||||
| Farallon Capital Offshore Investors II, L.P. | 0% | ||||
| Farallon Capital (AM) Investors, L.P. | 0% | ||||
| Farallon Capital F5 Master I, L.P. | 0% | ||||
| Farallon Partners, L.L.C. | 0% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0% | ||||
| Farallon F5 (GP), L.L.C. | 0% | ||||
| Dapice Joshua J. | 6.8% | ||||
| Dreyfuss, Philip D. | 6.8% | ||||
| Dunn Hannah E. | 6.8% | ||||
| Gehani, Varun N. | 6.8% | ||||
| Giauque, Nicolas | 6.8% | ||||
| Husen, Avner A. | 6.8% | ||||
| Kim, David T. | 6.8% | ||||
| Linn, Michael G. | 6.8% | ||||
| Luo Patrick (Cheng) | 6.8% | ||||
| Roberts, Jr., Thomas G. | 6.8% | ||||
| Saito Edric C. | 6.8% | ||||
| Short Daniel S. | 6.8% | ||||
| Spokes, Andrew J. M. | 6.8% | ||||
| Warren, John R. | 6.8% | ||||
| Wehrly, Mark C. | 6.8% | ||||
|
InflaRx N.V.
13G/A
Amendment 1
IFRX · N44821101
|
2.3% |
8/14/2026
Event 6/30/2026
|
|||
| Farallon Capital Management, L.L.C. | 2.3% | ||||
| Farallon Capital Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0% | ||||
| Four Crossings Institutional Partners V, L.P. | 0% | ||||
| Farallon Capital Offshore Investors II, L.P. | 0% | ||||
| Farallon Capital (AM) Investors, L.P. | 0% | ||||
| Farallon Capital F5 Master I, L.P. | 0% | ||||
| Farallon Partners, L.L.C. | 0% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0% | ||||
| Farallon F5 (GP), L.L.C. | 0% | ||||
| Dapice Joshua J. | 2.3% | ||||
| Dreyfuss, Philip D. | 2.3% | ||||
| Dunn Hannah E. | 2.3% | ||||
| Gehani, Varun N. | 2.3% | ||||
| Giauque, Nicolas | 2.3% | ||||
| Husen, Avner A. | 2.3% | ||||
| Kim, David T. | 2.3% | ||||
| Linn, Michael G. | 2.3% | ||||
| Luo Patrick (Cheng) | 2.3% | ||||
| Roberts, Jr., Thomas G. | 2.3% | ||||
| Saito Edric C. | 2.3% | ||||
| Short Daniel S. | 2.3% | ||||
| Spokes, Andrew J. M. | 2.3% | ||||
| Warren, John R. | 2.3% | ||||
| Wehrly, Mark C. | 2.3% | ||||
|
Exelixis, Inc.
13D/A
Amendment 8
EXEL · 30161Q104
|
5.6% |
8/14/2026
Event 8/14/2026
|
|||
| Farallon Capital Management, L.L.C. | 5.6% | ||||
| Farallon Capital Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0% | ||||
| Four Crossings Institutional Partners V, L.P. | 0% | ||||
| Farallon Capital Offshore Investors II, L.P. | 0% | ||||
| Farallon Capital (AM) Investors, L.P. | 0% | ||||
| Farallon Capital F5 Master I, L.P. | 0% | ||||
| Farallon Healthcare Partners Master, L.P. | 0% | ||||
| Farallon Partners, L.L.C. | 0% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0% | ||||
| Farallon F5 (GP), L.L.C. | 0% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 0% | ||||
| Dapice Joshua J. | 5.6% | ||||
| Dreyfuss, Philip D. | 5.6% | ||||
| Dunn Hannah E. | 5.6% | ||||
| Gehani, Varun N. | 5.6% | ||||
| Giauque, Nicolas | 5.6% | ||||
| Husen, Avner A. | 5.6% | ||||
| Kim, David T. | 5.6% | ||||
| Linn, Michael G. | 5.6% | ||||
| Luo Patrick (Cheng) | 5.6% | ||||
| Roberts, Jr., Thomas G. | 5.6% | ||||
| Saito Edric C. | 5.6% | ||||
| Short Daniel S. | 5.6% | ||||
| Spokes, Andrew J. M. | 5.6% | ||||
| Warren, John R. | 5.6% | ||||
| Wehrly, Mark C. | 5.6% | ||||
|
Enanta Pharmaceuticals Inc
13G/A
Amendment 8
ENTA · 29251M106
|
8.3% |
8/14/2026
Event 6/30/2026
|
|||
| Farallon Capital Management, L.L.C. | 8.3% | ||||
| Farallon Capital Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0% | ||||
| Four Crossings Institutional Partners V, L.P. | 0% | ||||
| Farallon Capital Offshore Investors II, L.P. | 0% | ||||
| Farallon Capital (AM) Investors, L.P. | 0% | ||||
| Farallon Capital F5 Master I, L.P. | 0% | ||||
| Farallon Partners, L.L.C. | 0% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0% | ||||
| Farallon F5 (GP), L.L.C. | 0% | ||||
| Dapice Joshua J. | 8.3% | ||||
| Dreyfuss, Philip D. | 8.3% | ||||
| Dunn Hannah E. | 8.3% | ||||
| Gehani, Varun N. | 8.3% | ||||
| Giauque, Nicolas | 8.3% | ||||
| Husen, Avner A. | 8.3% | ||||
| Kim, David T. | 8.3% | ||||
| Linn, Michael G. | 8.3% | ||||
| Luo Patrick (Cheng) | 8.3% | ||||
| Roberts, Jr., Thomas G. | 8.3% | ||||
| Saito Edric C. | 8.3% | ||||
| Short Daniel S. | 8.3% | ||||
| Spokes, Andrew J. M. | 8.3% | ||||
| Warren, John R. | 8.3% | ||||
| Wehrly, Mark C. | 8.3% | ||||
|
Revolution Medicines, Inc.
13G/A
Amendment 4
RVMD · 76155X100
|
6.4% |
8/13/2026
Event 6/30/2026
|
|||
| Farallon Capital Management, L.L.C. | 6.4% | ||||
| Farallon Capital Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0% | ||||
| Four Crossings Institutional Partners V, L.P. | 0% | ||||
| Farallon Capital Offshore Investors II, L.P. | 0% | ||||
| Farallon Capital (AM) Investors, L.P. | 0% | ||||
| Farallon Capital F5 Master I, L.P. | 0% | ||||
| Farallon Healthcare Partners Master, L.P. | 0% | ||||
| Farallon Partners, L.L.C. | 0% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0% | ||||
| Farallon F5 (GP), L.L.C. | 0% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 0% | ||||
| Dapice Joshua J. | 6.4% | ||||
| Dreyfuss, Philip D. | 6.4% | ||||
| Dunn Hannah E. | 6.4% | ||||
| Gehani, Varun N. | 6.4% | ||||
| Giauque, Nicolas | 6.4% | ||||
| Husen, Avner A. | 6.4% | ||||
| Kim, David T. | 6.4% | ||||
| Linn, Michael G. | 6.4% | ||||
| Luo Patrick (Cheng) | 6.4% | ||||
| Roberts, Jr., Thomas G. | 6.4% | ||||
| Saito Edric C. | 6.4% | ||||
| Short Daniel S. | 6.4% | ||||
| Spokes, Andrew J. M. | 6.4% | ||||
| Warren, John R. | 6.4% | ||||
| Wehrly, Mark C. | 6.4% | ||||
|
Protagonist Therapeutics, Inc.
13G/A
Amendment 9
PTGX · 74366E102
|
10.0% |
8/13/2026
Event 6/30/2026
|
|||
| Farallon Capital Management, L.L.C. | 10.0% | ||||
| Farallon Capital Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0% | ||||
| Four Crossings Institutional Partners V, L.P. | 0% | ||||
| Farallon Capital Offshore Investors II, L.P. | 0% | ||||
| Farallon Capital (AM) Investors, L.P. | 0% | ||||
| Farallon Capital F5 Master I, L.P. | 0% | ||||
| Farallon Healthcare Partners Master, L.P. | 0% | ||||
| Farallon Partners, L.L.C. | 0% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0% | ||||
| Farallon F5 (GP), L.L.C. | 0% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 0% | ||||
| Dapice Joshua J. | 10.0% | ||||
| Dreyfuss, Philip D. | 10.0% | ||||
| Dunn Hannah E. | 10.0% | ||||
| Gehani, Varun N. | 10.0% | ||||
| Giauque, Nicolas | 10.0% | ||||
| Husen, Avner A. | 10.0% | ||||
| Kim, David T. | 10.0% | ||||
| Linn, Michael G. | 10.0% | ||||
| Luo Patrick (Cheng) | 10.0% | ||||
| Roberts, Jr., Thomas G. | 10.0% | ||||
| Saito Edric C. | 10.0% | ||||
| Short Daniel S. | 10.0% | ||||
| Spokes, Andrew J. M. | 10.0% | ||||
| Warren, John R. | 10.0% | ||||
| Wehrly, Mark C. | 10.0% | ||||
|
Minerva Neurosciences, Inc.
13G/A
Amendment 2
NERV · 603380205
|
9.7% |
8/13/2026
Event 6/30/2026
|
|||
| Farallon Capital Management, L.L.C. | 9.7% | ||||
| Farallon Capital Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0% | ||||
| Four Crossings Institutional Partners V, L.P. | 0% | ||||
| Farallon Capital Offshore Investors II, L.P. | 0% | ||||
| Farallon Capital (AM) Investors, L.P. | 0% | ||||
| Farallon Capital F5 Master I, L.P. | 0% | ||||
| Farallon Partners, L.L.C. | 0% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0% | ||||
| Farallon F5 (GP), L.L.C. | 0% | ||||
| Dapice Joshua J. | 9.7% | ||||
| Dreyfuss, Philip D. | 9.7% | ||||
| Dunn Hannah E. | 9.7% | ||||
| Gehani, Varun N. | 9.7% | ||||
| Giauque, Nicolas | 9.7% | ||||
| Husen, Avner A. | 9.7% | ||||
| Kim, David T. | 9.7% | ||||
| Linn, Michael G. | 9.7% | ||||
| Luo Patrick (Cheng) | 9.7% | ||||
| Roberts, Jr., Thomas G. | 9.7% | ||||
| Saito Edric C. | 9.7% | ||||
| Short Daniel S. | 9.7% | ||||
| Spokes, Andrew J. M. | 9.7% | ||||
| Warren, John R. | 9.7% | ||||
| Wehrly, Mark C. | 9.7% | ||||
|
Lantheus Holdings, Inc.
13G/A
Amendment 5
CATX · 46489V104
|
8.6% |
8/13/2026
Event 6/30/2026
|
|||
| Farallon Capital Management, L.L.C. | 8.6% | ||||
| Farallon Capital Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0% | ||||
| Four Crossings Institutional Partners V, L.P. | 0% | ||||
| Farallon Capital Offshore Investors II, L.P. | 0% | ||||
| Farallon Capital (AM) Investors, L.P. | 0% | ||||
| Farallon Capital F5 Master I, L.P. | 0% | ||||
| Farallon Healthcare Partners Master, L.P. | 0% | ||||
| Farallon Partners, L.L.C. | 0% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0% | ||||
| Farallon F5 (GP), L.L.C. | 0% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 0% | ||||
| Dapice Joshua J. | 8.6% | ||||
| Dreyfuss, Philip D. | 8.6% | ||||
| Dunn Hannah E. | 8.6% | ||||
| Gehani, Varun N. | 8.6% | ||||
| Giauque, Nicolas | 8.6% | ||||
| Husen, Avner A. | 8.6% | ||||
| Kim, David T. | 8.6% | ||||
| Linn, Michael G. | 8.6% | ||||
| Luo Patrick (Cheng) | 8.6% | ||||
| Roberts, Jr., Thomas G. | 8.6% | ||||
| Saito Edric C. | 8.6% | ||||
| Short Daniel S. | 8.6% | ||||
| Spokes, Andrew J. M. | 8.6% | ||||
| Warren, John R. | 8.6% | ||||
| Wehrly, Mark C. | 8.6% | ||||
|
GRAIL, Inc.
13G/A
Amendment 3
GRAL · 384747101
|
9.6% |
8/13/2026
Event 6/30/2026
|
|||
| Farallon Capital Management, L.L.C. | 9.6% | ||||
| Farallon Capital Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0% | ||||
| Four Crossings Institutional Partners V, L.P. | 0% | ||||
| Farallon Capital Offshore Investors II, L.P. | 0% | ||||
| Farallon Capital (AM) Investors, L.P. | 0% | ||||
| Farallon Capital F5 Master I, L.P. | 0% | ||||
| Farallon Healthcare Partners Master, L.P. | 0% | ||||
| Farallon Partners, L.L.C. | 0% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0% | ||||
| Farallon F5 (GP), L.L.C. | 0% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 0% | ||||
| Dapice Joshua J. | 9.6% | ||||
| Dreyfuss, Philip D. | 9.6% | ||||
| Dunn Hannah E. | 9.6% | ||||
| Gehani, Varun N. | 9.6% | ||||
| Giauque, Nicolas | 9.6% | ||||
| Husen, Avner A. | 9.6% | ||||
| Kim, David T. | 9.6% | ||||
| Linn, Michael G. | 9.6% | ||||
| Luo Patrick (Cheng) | 9.6% | ||||
| Roberts, Jr., Thomas G. | 9.6% | ||||
| Saito Edric C. | 9.6% | ||||
| Short Daniel S. | 9.6% | ||||
| Spokes, Andrew J. M. | 9.6% | ||||
| Warren, John R. | 9.6% | ||||
| Wehrly, Mark C. | 9.6% | ||||
|
Beam Therapeutics Inc.
13G/A
Amendment 6
BEAM · 07373V105
|
10.0% |
8/13/2026
Event 6/30/2026
|
|||
| Farallon Capital Management, L.L.C. | 10.0% | ||||
| Farallon Capital Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0% | ||||
| Four Crossings Institutional Partners V, L.P. | 0% | ||||
| Farallon Capital Offshore Investors II, L.P. | 0% | ||||
| Farallon Capital (AM) Investors, L.P. | 0% | ||||
| Farallon Capital F5 Master I, L.P. | 0% | ||||
| Farallon Healthcare Partners Master, L.P. | 0% | ||||
| Farallon Partners, L.L.C. | 0% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0% | ||||
| Farallon F5 (GP), L.L.C. | 0% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 0% | ||||
| Dapice Joshua J. | 10.0% | ||||
| Dreyfuss, Philip D. | 10.0% | ||||
| Dunn Hannah E. | 10.0% | ||||
| Gehani, Varun N. | 10.0% | ||||
| Giauque, Nicolas | 10.0% | ||||
| Husen, Avner A. | 10.0% | ||||
| Kim, David T. | 10.0% | ||||
| Linn, Michael G. | 10.0% | ||||
| Luo Patrick (Cheng) | 10.0% | ||||
| Roberts, Jr., Thomas G. | 10.0% | ||||
| Saito Edric C. | 10.0% | ||||
| Short Daniel S. | 10.0% | ||||
| Spokes, Andrew J. M. | 10.0% | ||||
| Warren, John R. | 10.0% | ||||
| Wehrly, Mark C. | 10.0% | ||||
|
Beta Bionics, Inc.
13G/A
Amendment 5
BBNX · 08659B102
|
1.3% |
8/13/2026
Event 6/30/2026
|
|||
| Farallon Capital Management, L.L.C. | 1.3% | ||||
| Zone Healthcare Holdings, LLC | 0% | ||||
| Farallon Capital Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0% | ||||
| Four Crossings Institutional Partners V, L.P. | 0% | ||||
| Farallon Capital Offshore Investors II, L.P. | 0% | ||||
| Farallon Capital (AM) Investors, L.P. | 0% | ||||
| Farallon Capital F5 Master I, L.P. | 0% | ||||
| Farallon Partners, L.L.C. | 0% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0% | ||||
| Farallon F5 (GP), L.L.C. | 0% | ||||
| Dapice Joshua J. | 1.3% | ||||
| Dreyfuss, Philip D. | 1.3% | ||||
| Dunn Hannah E. | 1.3% | ||||
| Gehani, Varun N. | 1.3% | ||||
| Giauque, Nicolas | 1.3% | ||||
| Husen, Avner A. | 1.3% | ||||
| Kim, David T. | 1.3% | ||||
| Linn, Michael G. | 1.3% | ||||
| Luo Patrick (Cheng) | 1.3% | ||||
| Roberts, Jr., Thomas G. | 1.3% | ||||
| Saito Edric C. | 1.3% | ||||
| Short Daniel S. | 1.3% | ||||
| Spokes, Andrew J. M. | 1.3% | ||||
| Warren, John R. | 1.3% | ||||
| Wehrly, Mark C. | 1.3% | ||||
|
Liquidia Corporation
13G/A
Amendment 3
LQDA · 53635D202
|
9.4% |
8/4/2026
Event 6/30/2026
|
|||
| Farallon Capital Management, L.L.C. | 9.4% | ||||
| Farallon Capital Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0% | ||||
| Four Crossings Institutional Partners V, L.P. | 0% | ||||
| Farallon Capital Offshore Investors II, L.P. | 0% | ||||
| Farallon Capital (AM) Investors, L.P. | 0% | ||||
| Farallon Capital F5 Master I, L.P. | 0% | ||||
| Farallon Healthcare Partners Master, L.P. | 0% | ||||
| Farallon Partners, L.L.C. | 0% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0% | ||||
| Farallon F5 (GP), L.L.C. | 0% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 0% | ||||
| Dapice Joshua J. | 9.4% | ||||
| Dreyfuss, Philip D. | 9.4% | ||||
| Dunn Hannah E. | 9.4% | ||||
| Gehani, Varun N. | 9.4% | ||||
| Giauque, Nicolas | 9.4% | ||||
| Husen, Avner A. | 9.4% | ||||
| Kim, David T. | 9.4% | ||||
| Linn, Michael G. | 9.4% | ||||
| Luo Patrick (Cheng) | 9.4% | ||||
| Roberts, Jr., Thomas G. | 9.4% | ||||
| Saito Edric C. | 9.4% | ||||
| Short Daniel S. | 9.4% | ||||
| Spokes, Andrew J. M. | 9.4% | ||||
| Warren, John R. | 9.4% | ||||
| Wehrly, Mark C. | 9.4% | ||||
|
Assembly Biosciences, Inc.
13G/A
Amendment 2
ASMB · 045396207
|
8.1% |
8/4/2026
Event 6/30/2026
|
|||
| Farallon Capital Management, L.L.C. | 8.1% | ||||
| Farallon Capital Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0% | ||||
| Four Crossings Institutional Partners V, L.P. | 0% | ||||
| Farallon Capital Offshore Investors II, L.P. | 0% | ||||
| Farallon Capital (AM) Investors, L.P. | 0% | ||||
| Farallon Capital F5 Master I, L.P. | 0% | ||||
| Farallon Partners, L.L.C. | 0% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0% | ||||
| Farallon F5 (GP), L.L.C. | 0% | ||||
| Dapice Joshua J. | 8.1% | ||||
| Dreyfuss, Philip D. | 8.1% | ||||
| Dunn Hannah E. | 8.1% | ||||
| Gehani, Varun N. | 8.1% | ||||
| Giauque, Nicolas | 8.1% | ||||
| Husen, Avner A. | 8.1% | ||||
| Kim, David T. | 8.1% | ||||
| Linn, Michael G. | 8.1% | ||||
| Luo Patrick (Cheng) | 8.1% | ||||
| Roberts, Jr., Thomas G. | 8.1% | ||||
| Saito Edric C. | 8.1% | ||||
| Short Daniel S. | 8.1% | ||||
| Spokes, Andrew J. M. | 8.1% | ||||
| Warren, John R. | 8.1% | ||||
| Wehrly, Mark C. | 8.1% | ||||
|
BridgeBio Pharma, Inc.
13G/A
Amendment 1
BBIO · 10806X102
|
5.5% |
8/3/2026
Event 6/30/2026
|
|||
| Farallon Capital Management, L.L.C. | 5.5% | ||||
| Farallon Capital Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0% | ||||
| Four Crossings Institutional Partners V, L.P. | 0% | ||||
| Farallon Capital Offshore Investors II, L.P. | 0% | ||||
| Farallon Capital (AM) Investors, L.P. | 0% | ||||
| Farallon Capital F5 Master I, L.P. | 0% | ||||
| Farallon Healthcare Partners Master, L.P. | 0% | ||||
| Farallon Partners, L.L.C. | 0% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0% | ||||
| Farallon F5 (GP), L.L.C. | 0% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 0% | ||||
| Dapice Joshua J. | 5.5% | ||||
| Dreyfuss, Philip D. | 5.5% | ||||
| Dunn Hannah E. | 5.5% | ||||
| Gehani, Varun N. | 5.5% | ||||
| Giauque, Nicolas | 5.5% | ||||
| Husen, Avner A. | 5.5% | ||||
| Kim, David T. | 5.5% | ||||
| Linn, Michael G. | 5.5% | ||||
| Luo Patrick (Cheng) | 5.5% | ||||
| Roberts, Jr., Thomas G. | 5.5% | ||||
| Saito Edric C. | 5.5% | ||||
| Short Daniel S. | 5.5% | ||||
| Spokes, Andrew J. M. | 5.5% | ||||
| Warren, John R. | 5.5% | ||||
| Wehrly, Mark C. | 5.5% | ||||
|
Agios Pharmaceuticals, Inc.
13G/A
Amendment 5
AGIO · 00847X104
|
9.9% |
8/3/2026
Event 6/30/2026
|
|||
| Farallon Capital Management, L.L.C. | 9.9% | ||||
| Farallon Capital Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0% | ||||
| Four Crossings Institutional Partners V, L.P. | 0% | ||||
| Farallon Capital Offshore Investors II, L.P. | 0% | ||||
| Farallon Capital (AM) Investors, L.P. | 0% | ||||
| Farallon Capital F5 Master I, L.P. | 0% | ||||
| Farallon Healthcare Partners Master, L.P. | 0% | ||||
| Farallon Partners, L.L.C. | 0% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0% | ||||
| Farallon F5 (GP), L.L.C. | 0% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 0% | ||||
| Dapice Joshua J. | 9.9% | ||||
| Dreyfuss, Philip D. | 9.9% | ||||
| Dunn Hannah E. | 9.9% | ||||
| Gehani, Varun N. | 9.9% | ||||
| Giauque, Nicolas | 9.9% | ||||
| Husen, Avner A. | 9.9% | ||||
| Kim, David T. | 9.9% | ||||
| Linn, Michael G. | 9.9% | ||||
| Luo Patrick (Cheng) | 9.9% | ||||
| Roberts, Jr., Thomas G. | 9.9% | ||||
| Saito Edric C. | 9.9% | ||||
| Short Daniel S. | 9.9% | ||||
| Spokes, Andrew J. M. | 9.9% | ||||
| Warren, John R. | 9.9% | ||||
| Wehrly, Mark C. | 9.9% | ||||
|
Crinetics Pharmaceuticals, Inc.
13G/A
Amendment 2
CRNX · 22663K107
|
8.5% |
8/3/2026
Event 6/30/2026
|
|||
| Farallon Capital Management, L.L.C. | 8.5% | ||||
| Farallon Capital Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0% | ||||
| Four Crossings Institutional Partners V, L.P. | 0% | ||||
| Farallon Capital Offshore Investors II, L.P. | 0% | ||||
| Farallon Capital (AM) Investors, L.P. | 0% | ||||
| Farallon Capital F5 Master I, L.P. | 0% | ||||
| Farallon Healthcare Partners Master, L.P. | 0% | ||||
| Farallon Partners, L.L.C. | 0% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0% | ||||
| Farallon F5 (GP), L.L.C. | 0% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 0% | ||||
| Dapice Joshua J. | 8.5% | ||||
| Dreyfuss, Philip D. | 8.5% | ||||
| Dunn Hannah E. | 8.5% | ||||
| Gehani, Varun N. | 8.5% | ||||
| Giauque, Nicolas | 8.5% | ||||
| Husen, Avner A. | 8.5% | ||||
| Kim, David T. | 8.5% | ||||
| Linn, Michael G. | 8.5% | ||||
| Luo Patrick (Cheng) | 8.5% | ||||
| Roberts, Jr., Thomas G. | 8.5% | ||||
| Saito Edric C. | 8.5% | ||||
| Short Daniel S. | 8.5% | ||||
| Spokes, Andrew J. M. | 8.5% | ||||
| Warren, John R. | 8.5% | ||||
| Wehrly, Mark C. | 8.5% | ||||
|
Centessa Pharmaceuticals plc
13D/A
Amendment 1
CNTA · 152309100
|
0% |
6/26/2026
Event 6/24/2026
|
|||
| Farallon Capital Management, L.L.C. | 0% | ||||
| Dapice Joshua J. | 0% | ||||
| Dreyfuss, Philip D. | 0% | ||||
| Dunn Hannah E. | 0% | ||||
| Gehani, Varun N. | 0% | ||||
| Giauque, Nicolas | 0% | ||||
| Husen, Avner A. | 0% | ||||
| Kim, David T. | 0% | ||||
| Linn, Michael G. | 0% | ||||
| Luo Patrick (Cheng) | 0% | ||||
| Roberts, Jr., Thomas G. | 0% | ||||
| Saito Edric C. | 0% | ||||
| Short Daniel S. | 0% | ||||
| Spokes, Andrew J. M. | 0% | ||||
| Warren, John R. | 0% | ||||
| Wehrly, Mark C. | 0% | ||||
|
Centessa Pharmaceuticals plc
13D
CNTA · 152309100
|
6.1% |
6/24/2026
Event 6/16/2026
|
|||
| Farallon Capital Management, L.L.C. | 6.1% | ||||
| Dapice Joshua J. | 6.1% | ||||
| Dreyfuss, Philip D. | 6.1% | ||||
| Dunn Hannah E. | 6.1% | ||||
| Gehani, Varun N. | 6.1% | ||||
| Giauque, Nicolas | 6.1% | ||||
| Husen, Avner A. | 6.1% | ||||
| Kim, David T. | 6.1% | ||||
| Linn, Michael G. | 6.1% | ||||
| Luo Patrick (Cheng) | 6.1% | ||||
| Roberts, Jr., Thomas G. | 6.1% | ||||
| Saito Edric C. | 6.1% | ||||
| Short Daniel S. | 6.1% | ||||
| Spokes, Andrew J. M. | 6.1% | ||||
| Warren, John R. | 6.1% | ||||
| Wehrly, Mark C. | 6.1% | ||||
|
Marblegate Acquisition Corp.
13G/A
Amendment 6
GATE · 56608A105
|
0% |
8/13/2025
Event 6/30/2025
|
|||
| Grassland Investors, LLC | 0% | ||||
| Farallon Capital Management, L.L.C. | 0% | ||||
| Dapice Joshua J. | 0% | ||||
| Dreyfuss, Philip D. | 0% | ||||
| Dunn Hannah E. | 0% | ||||
| Fried, Richard B | 0% | ||||
| Gehani, Varun N. | 0% | ||||
| Giauque, Nicolas | 0% | ||||
| Kim, David T. | 0% | ||||
| Linn, Michael G. | 0% | ||||
| Luo Patrick (Cheng) | 0% | ||||
| Patel, Rajiv A. | 0% | ||||
| Roberts, Jr., Thomas G. | 0% | ||||
| Saito Edric C. | 0% | ||||
| Seybold, William | 0% | ||||
| Short Daniel S. | 0% | ||||
| Spokes, Andrew J. M. | 0% | ||||
| Warren, John R. | 0% | ||||
| Wehrly, Mark C. | 0% | ||||